Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONYX study of quetiapine SR add-on therapy in major depressive disorder with inadequate antidepressant response
2005-005053-22Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Seroquel SR + antidepressant with Placebo + antidepressant (2 arms). Primary endpoint: Change in MADRS total score. Started Feb 2006; status: completed.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-005053-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005053-22.